G-CSFR Activators
The Granulocyte Colony-Stimulating Factor Receptor (G-CSFR), encoded by the CSF3R gene, is a crucial transmembrane receptor primarily found on the surface of hematopoietic stem cells and mature granulocytes. Its main function is to regulate the production, proliferation, and differentiation of granulocyte lineage cells, which include neutrophils, eosinophils, and basophils. Activation of G-CSFR occurs upon binding with its ligand, Granulocyte Colony-Stimulating Factor (G-CSF), leading to a series of intracellular signaling events that culminate in the promotion of granulopoiesis and cell survival.
The general mechanism of G-CSFR activation involves the binding of G-CSF to its extracellular domain, triggering conformational changes in the receptor that promote dimerization and transphosphorylation of intracellular tyrosine residues within the receptor's cytoplasmic domain. This activation leads to the recruitment and activation of Janus kinase (JAK) family members, particularly JAK2, which phosphorylate specific tyrosine residues on the receptor itself. Phosphorylation of these tyrosine residues serves as docking sites for signal transducer and activator of transcription (STAT) proteins, allowing them to be phosphorylated by JAKs. Phosphorylated STAT proteins then form homo- or heterodimers and translocate to the nucleus, where they act as transcription factors, regulating the expression of genes involved in granulocyte differentiation, proliferation, and survival. Additionally, G-CSFR activation also stimulates other downstream signaling pathways such as the Ras/Raf/MEK/ERK pathway, phosphatidylinositol 3-kinase (PI3K)/Akt pathway, and Src family kinases, further enhancing granulopoiesis and cellular responses. Overall, the activation of G-CSFR plays a pivotal role in orchestrating the production and function of granulocytes, contributing to the maintenance of innate immunity and host defense against infections.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Lithium chloride influences the Wnt/β-catenin signaling pathway. This indirect activation of G-CSFR occurs through the modulation of β-catenin, leading to increased expression of G-CSFR. The Wnt/β-catenin pathway plays a role in hematopoiesis, and lithium chloride's impact on this pathway can potentially activate G-CSFR by promoting the cellular processes associated with G-CSFR expression and activation. | ||||||
Valproic Acid | 99-66-1 | sc-213144 | 10 g | $85.00 | 9 | |
Valproic acid, a histone deacetylase (HDAC) inhibitor, modulates gene expression epigenetically. Its indirect activation of G-CSFR involves the regulation of chromatin structure and histone acetylation, leading to increased G-CSFR expression. By influencing the epigenetic landscape, valproic acid can potentially activate G-CSFR by enhancing the accessibility of the G-CSFR gene and promoting transcriptional processes associated with G-CSFR activation. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $60.00 $185.00 $365.00 | 64 | |
Resveratrol is a polyphenolic compound that activates the SIRT1 enzyme. Its indirect activation of G-CSFR occurs through SIRT1-mediated deacetylation, impacting the expression of genes involved in hematopoiesis, including G-CSFR. By influencing the acetylation status of histones and transcription factors, resveratrol can potentially activate G-CSFR by modulating the epigenetic regulation of G-CSFR expression and associated cellular processes. | ||||||
AMD 3465 hexahydrobromide | 185991-07-5 | sc-362709 sc-362709A | 10 mg 50 mg | $185.00 $772.00 | ||
AMD3465 is a CXCR4 antagonist that indirectly activates G-CSFR by mobilizing hematopoietic stem cells from the bone marrow. By blocking CXCR4, AMD3465 enhances the release of G-CSFR-expressing stem cells into the peripheral blood, promoting their differentiation and activation. This indirect activation of G-CSFR is mediated through the modulation of hematopoietic processes influenced by the CXCR4 receptor. | ||||||
Tranylcypromine | 13492-01-8 | sc-200572 sc-200572A | 1 g 5 g | $172.00 $587.00 | 5 | |
Tranylcypromine, a monoamine oxidase inhibitor, influences the cellular levels of neurotransmitters and also impacts cellular processes related to G-CSFR. Its indirect activation of G-CSFR occurs through the modulation of intracellular signaling events, possibly involving neurotransmitter-mediated pathways. By influencing cellular signaling, tranylcypromine can potentially activate G-CSFR by promoting the intracellular events associated with G-CSFR activation. | ||||||
Zileuton | 111406-87-2 | sc-204417 sc-204417A sc-204417B sc-204417C | 10 mg 50 mg 1 g 75 g | $82.00 $301.00 $362.00 $1229.00 | 8 | |
Zileuton is a 5-lipoxygenase (5-LOX) inhibitor that indirectly activates G-CSFR through the modulation of the arachidonic acid pathway. By inhibiting 5-LOX, zileuton impacts the synthesis of leukotrienes, which can influence cellular processes associated with G-CSFR activation. This indirect activation of G-CSFR is mediated through the regulation of lipid-derived signaling molecules involved in hematopoiesis and inflammatory responses. | ||||||
Rosiglitazone | 122320-73-4 | sc-202795 sc-202795A sc-202795C sc-202795D sc-202795B | 25 mg 100 mg 500 mg 1 g 5 g | $118.00 $320.00 $622.00 $928.00 $1234.00 | 38 | |
Rosiglitazone, a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist, influences cellular processes related to G-CSFR activation. Its indirect activation of G-CSFR occurs through the modulation of PPAR-γ-regulated pathways, possibly involving adipocyte-derived signals. By activating PPAR-γ, rosiglitazone can potentially influence cellular events associated with G-CSFR activation, promoting hematopoietic processes and G-CSFR expression. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $65.00 $319.00 $575.00 $998.00 | 28 | |
All-trans retinoic acid (ATRA) is a retinoid compound that indirectly activates G-CSFR through retinoic acid receptor (RAR) signaling. By binding to RAR, ATRA influences gene expression related to hematopoiesis, including G-CSFR. This indirect activation of G-CSFR is mediated through the modulation of retinoid-regulated pathways, impacting cellular processes associated with G-CSFR expression and activation. | ||||||
PGE2 | 363-24-6 | sc-201225 sc-201225C sc-201225A sc-201225B | 1 mg 5 mg 10 mg 50 mg | $56.00 $156.00 $270.00 $665.00 | 37 | |
Prostaglandin E2 (PGE2) is a lipid mediator that can indirectly activate G-CSFR through its impact on hematopoietic and inflammatory processes. By influencing prostaglandin signaling, PGE2 can modulate cellular events associated with G-CSFR activation. This indirect activation is mediated through the regulation of prostaglandin-dependent pathways involved in hematopoiesis and immune responses, leading to the promotion of G-CSFR expression and activation. | ||||||
9-cis-Retinoic acid | 5300-03-8 | sc-205589 sc-205589B sc-205589C sc-205589D sc-205589A | 1 mg 25 mg 250 mg 500 mg 5 mg | $70.00 $416.00 $3060.00 $5610.00 $145.00 | 10 | |
9-cis-retinoic acid is an isomer of ATRA and a retinoid compound that can indirectly activate G-CSFR through retinoic acid receptor (RAR) signaling. By binding to RAR, 9-cis-retinoic acid influences gene expression related to hematopoiesis, including G-CSFR. This indirect activation of G-CSFR is mediated through the modulation of retinoid-regulated pathways, impacting cellular processes associated with G-CSFR expression and activation. | ||||||